NeuroSense Therapeutics (NRSN) Short Interest Ratio & Short Volume → Log Into Marc's $5,000 System Today (From Chaikin Analytics) (Ad) Free NRSN Stock Alerts $1.09 -0.08 (-6.84%) (As of 05/28/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends NeuroSense Therapeutics Short Interest DataCurrent Short Interest20,600 sharesPrevious Short Interest18,200 sharesChange Vs. Previous Month+13.19%Dollar Volume Sold Short$24,678.80Short Interest Ratio0.1 Days to CoverLast Record DateMay 15, 2024Outstanding Shares13,670,000 sharesFloat Size12,460,000 sharesShort Percent of Float0.17%Today's Trading Volume71,080 sharesAverage Trading Volume235,669 sharesToday's Volume Vs. Average30% Short Selling NeuroSense Therapeutics ? Sign up to receive the latest short interest report for NeuroSense Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartNRSN Short Interest Over TimeNRSN Days to Cover Over TimeNRSN Percentage of Float Shorted Over Time Ad Chaikin AnalyticsLog Into Marc's $5,000 System TodayNew Panic Could Sweep America Mark these words in 2024. Everyone's going to cash… Wall Street legend says: "A little-known vehicle outside of banks could double… triple… or even quadruple your life savings if you know where to find it right now." We urge you to move your cash into this vehicle in 2024. More here. NeuroSense Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/15/202420,600 shares $24,678.80 +13.2%0.2%0.1 $1.20 4/30/202418,200 shares $24,570.00 -79.4%0.2%0.1 $1.35 4/15/202488,400 shares $135,252.00 +38.8%0.8%0.3 $1.53 3/31/202463,700 shares $115,934.00 +81.5%0.7%0.2 $1.82 3/15/202435,100 shares $48,438.00 -83.4%0.4%0.1 $1.38 2/29/2024211,400 shares $374,178.00 +42.0%2.3%0.5 $1.77 Get the Latest News and Ratings for NRSN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for NeuroSense Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/15/2024148,900 shares $198,037.00 +12.7%1.6%0.2 $1.33 1/31/2024132,100 shares $165,125.00 -35.6%1.5%0.2 $1.25 1/15/2024205,200 shares $175,261.32 -17.7%2.3%0.2 $0.85 12/31/2023249,200 shares $195,622.00 +18.7%2.7%0.3 $0.79 12/15/2023210,000 shares $176,631.00 +1.9%2.3%0.2 $0.84 11/30/2023206,100 shares $265,869.00 -11.9%2.3%0.3 $1.29 11/15/2023234,000 shares $120,276.00 +89.3%2.6%1 $0.51 10/31/2023123,600 shares $56,930.16 +182.2%1.4%0.6 $0.46 10/15/202343,800 shares $23,956.67 +91.3%0.5%0.3 $0.55 9/30/202322,900 shares $16,259.00 -3.8%0.3%0.3 $0.71 9/15/202323,800 shares $20,944.00 +9.2%0.3%0.6 $0.88 8/31/202321,800 shares $20,492.00 +77.2%0.2%0.5 $0.94 8/15/202312,300 shares $11,808.00 -37.6%0.1%0.2 $0.96 7/31/202319,700 shares $25,610.00 -53.4%0.3%0.3 $1.30 7/15/202342,300 shares $57,528.00 -38.3%0.6%0.5 $1.36 6/30/202368,600 shares $102,214.00 -12.4%1.0%0.9 $1.49 6/15/202378,300 shares $144,072.00 -38.8%1.2%1 $1.84 5/31/2023127,900 shares $199,524.00 -13.6%1.9%1.9 $1.56 5/15/2023148,000 shares $253,080.00 -1.7%2.2%2.9 $1.71 4/30/2023150,600 shares $304,212.00 -12.0%2.2%2 $2.02 4/15/2023171,100 shares $278,893.00 -8.2%2.5%1.4 $1.63 3/31/2023186,300 shares $320,436.00 -6.1%2.8%0.1 $1.72 3/15/2023198,300 shares $354,957.00 -6.4%3.1%0.1 $1.79 2/28/2023211,800 shares $393,948.00 -10.1%3.1%0.2 $1.86 2/15/2023235,700 shares $393,619.00 +8.2%3.4%0.2 $1.67 1/31/2023217,900 shares $337,745.00 +1,479.0%3.2%0.2 $1.55 1/15/202313,800 shares $18,630.00 -25.0%0.2%0 $1.35 12/30/202218,400 shares $22,448.00 -24.6%0.3%0.7 $1.22 12/15/202224,400 shares $37,332.00 -22.0%0.4%0.8 $1.53 11/30/202231,300 shares $53,836.00 +30.4%0.5%0.9 $1.72 11/15/202224,000 shares $40,800.00 -21.8%0.4%0.6 $1.70 10/31/202230,700 shares $49,120.00 -40.0%0.5%0.8 $1.60 10/15/202251,200 shares $87,552.00 -53.7%0.7%0.7 $1.71 9/30/2022110,500 shares $197,795.00 +269.6%1.6%1.1 $1.79Log Into Marc's $5,000 System Today (Ad)New Panic Could Sweep America Mark these words in 2024. Everyone's going to cash… Wall Street legend says: "A little-known vehicle outside of banks could double… triple… or even quadruple your life savings if you know where to find it right now." We urge you to move your cash into this vehicle in 2024. More here. 9/15/202229,900 shares $61,893.00 +13.7%0.4%0 $2.07 8/31/202226,300 shares $51,285.00 -46.8%0.4%0 $1.95 8/15/202249,400 shares $111,150.00 +31.4%0.8%0 $2.25 7/31/202237,600 shares $70,312.00 -36.5%0.6%0 $1.87 7/15/202259,200 shares $121,952.00 -91.8%0.9%0 $2.06 6/30/2022719,900 shares $2.43 million +302.4%11.7%0.2 $3.38 6/15/2022178,900 shares $305,919.00 +1.6%2.9%0.2 $1.71 5/31/2022176,100 shares $248,301.00 +78.8%2.9%0 $1.41 5/15/202298,500 shares $125,095.00 +64.2%1.6%0 $1.27 4/30/202260,000 shares $100,800.00 +26.3%1.0%0 $1.68 4/15/202247,500 shares $95,950.00 -86.3%N/A0 $2.02 3/31/2022347,000 shares $1.38 million +568.6%5.7%0.1 $3.97 3/15/202251,900 shares $72,660.00 +464.1%0.9%0 $1.40 2/28/20229,200 shares $23,920.00 +187.5%0.2%0 $2.60 2/15/20223,200 shares $5,568.00 -38.5%0.1%0 $1.74 1/31/20225,200 shares $10,244.00 -80.4%0.1%0 $1.97 1/15/202226,500 shares $72,875.00 +69.9%0.4%0.1 $2.75 12/31/202115,600 shares $38,376.00 No Change0.3%0 $2.46 NRSN Short Interest - Frequently Asked Questions What is NeuroSense Therapeutics' current short interest? Short interest is the volume of NeuroSense Therapeutics shares that have been sold short but have not yet been covered or closed out. As of May 15th, traders have sold 20,600 shares of NRSN short. 0.17% of NeuroSense Therapeutics' shares are currently sold short. Learn More on NeuroSense Therapeutics' current short interest. What is a good short interest percentage for NeuroSense Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.17% of NeuroSense Therapeutics' floating shares are currently sold short. Is NeuroSense Therapeutics' short interest increasing or decreasing? NeuroSense Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 20,600 shares, an increase of 13.2% from the previous total of 18,200 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is NeuroSense Therapeutics' float size? NeuroSense Therapeutics currently has issued a total of 13,670,000 shares. Some of NeuroSense Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. NeuroSense Therapeutics currently has a public float of 12,460,000 shares. How does NeuroSense Therapeutics' short interest compare to its competitors? 0.17% of NeuroSense Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to NeuroSense Therapeutics: Minerva Neurosciences, Inc. (0.50%), Aytu BioPharma, Inc. (7.82%), Galecto, Inc. (0.24%), Orgenesis Inc. (0.72%), Tonix Pharmaceuticals Holding Corp. (0.82%), GlycoMimetics, Inc. (3.63%), Talphera, Inc. (0.72%), KALA BIO, Inc. (0.25%), VBI Vaccines Inc. (1.18%), Vincerx Pharma, Inc. (1.92%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks. What does it mean to sell short NeuroSense Therapeutics stock? Short selling NRSN is an investing strategy that aims to generate trading profit from NeuroSense Therapeutics as its price is falling. NRSN shares are trading down $0.08 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against NeuroSense Therapeutics? A short squeeze for NeuroSense Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of NRSN, which in turn drives the price of the stock up even further. How often is NeuroSense Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including NRSN, twice per month. The most recent reporting period available is May, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Minerva Neurosciences Short Interest Data Aytu BioPharma Short Interest Data Galecto Short Interest Data Orgenesis Short Interest Data Tonix Pharmaceuticals Short Interest Data GlycoMimetics Short Interest Data Talphera Short Interest Data KALA BIO Short Interest Data VBI Vaccines Short Interest Data Vincerx Pharma Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:NRSN) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersWARNING about the death of the U.S. dollar…Colonial MetalsDigitizing the $11T commodities sector with one tiny stockResource Stock DigestTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy SykesBiggest Prediction of My 50-Year Career on Wall StreetChaikin AnalyticsElon’s New Device is About to Shock the WorldInvestorPlaceHe Is Giving Away BitcoinCrypto Swap ProfitsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroSense Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.